Tesamorelin certificate of analysis explained

Last updated 2026-07-25

What is a tesamorelin certificate of analysis, exactly?

A certificate of analysis is a document a lab issues after testing a specific batch of a substance. For a peptide like tesamorelin, a real COA typically reports four things: identity (is this molecule actually tesamorelin, confirmed by mass spectrometry or HPLC retention time), purity (what percentage of the vial's peptide content is the intended molecule versus degradation products or truncated sequences), residual solvents or moisture content, and microbial/endotoxin testing if the product claims to be sterile. The key thing to understand up front: a COA is a snapshot of one batch, tested by one lab, at one point in time. It says nothing about how the product was stored, whether the vial you receive matches the batch tested, or whether the lab itself is competent or independent. A COA from an unaccredited lab, or one paid for by the seller with no third-party verification, is worth far less than the paper it's printed on suggests. This matters more for tesamorelin than for a lot of other peptides. The molecule is a 44-amino-acid growth hormone-releasing factor analogue, and synthesis errors (truncated chains, oxidized residues, incomplete amidation) are common failure modes in peptide manufacturing generally ^[1]. Analytical detection of GHRH analogues and their degradation products has been a specific focus of drug-testing labs, partly because these molecules are also monitored in anti-doping contexts ^[2]. If you're new to how this drug is dosed once sourced properly, our guide on tesamorelin how to inject covers the practical side.

Does FDA-approved tesamorelin (Egrifta) come with a certificate of analysis?

No, not in the way people mean when they ask this question. Egrifta (tesamorelin for injection) is an FDA-approved drug, listed in the Drugs@FDA database, manufactured under Current Good Manufacturing Practice (cGMP) requirements with FDA inspection oversight [Drugs@FDA]. Patients receiving Egrifta through a licensed pharmacy are not expected to review a batch COA themselves, because the entire chain from manufacturer to pharmacy is already regulated and audited. This is the single biggest thing to understand before you go COA-hunting: asking for a certificate of analysis is a workaround people use when a product sits outside FDA drug approval, typically because it's compounded from bulk powder or sold as a 'research chemical.' If you're being handed a COA as reassurance, ask yourself why the seller isn't simply pointing you to FDA approval instead. Egrifta's approved indication is narrow. It covers reduction of excess visceral adipose tissue in HIV-infected patients with lipodystrophy ^{[3] [4]}. That approval, and the phase 3 evidence behind it, doesn't extend to general fat loss, anti-aging use, or bodybuilding-adjacent goals. Using tesamorelin for those purposes is off-label, and off-label use is where compounded, COA-dependent products tend to enter the picture. See our companion piece on how long tesamorelin takes to work for what the approved trials actually measured.

Why would a tesamorelin product need a COA at all?

Compounded tesamorelin, made by a 503A or 503B pharmacy from bulk active pharmaceutical ingredient, is legally distinct from FDA-approved Egrifta. Bulk drug substances used in compounding are governed by 21 CFR 216.23 for 503A pharmacies and 21 CFR 216.24 for 503B outsourcing facilities, and by the compounding provisions at 21 U.S.C. 353a ^{[5] [6] [7]}. Compounders sourcing bulk tesamorelin powder are supposed to verify the raw material meets identity and quality standards, and a COA from the raw-material supplier is one input into that verification. The problem: a raw-material COA describes the powder before compounding, not the finished, reconstituted product a patient injects. Compounding introduces its own variables. Dilution accuracy, sterility of the compounding environment, and stability after reconstitution are all things a bulk powder COA never addresses. A clean COA on the API doesn't guarantee a clean finished product. Separately, there's a whole gray market of 'research use only' tesamorelin sold outside any pharmacy relationship, where a COA (often unverifiable, sometimes reused across batches) is the only quality claim offered. That's a materially different risk category from either FDA-approved Egrifta or legitimate 503A/503B compounding, and it's outside anything the phase 3 trial data or FDA oversight actually covers.

What should a legitimate tesamorelin COA actually show?

If you are evaluating a COA (for example, as a pharmacist or compounder checking a bulk lot), the minimum useful document includes a specific batch/lot number matching the product in hand, an HPLC purity result (look for the percentage and the method), a mass spectrometry identity confirmation, and, for injectable use, sterility and endotoxin test results with numeric limits, more than a pass/fail checkbox. A vague COA that says 'purity: high' or lists no lot number is not a real quality document. Neither is a COA where the testing lab isn't named, or where the lab is owned by the same company selling the product. Third-party, accredited lab testing is the baseline for any COA claim to mean something. Here's a practical table of what separates a usable COA from a decorative one: | COA element | Meaningful version | Red flag version |

What does the phase 3 evidence actually say tesamorelin does?

This is worth separating cleanly from the COA question, because a lot of buyer confusion comes from blending 'is this vial legitimate' with 'does this drug work.' The approved evidence is specific and narrow. A pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials in HIV-infected patients with excess abdominal fat, including safety extension data, supports the approved reduction in visceral adipose tissue ^[8]. Tesamorelin has also been shown to reduce liver fat and improve markers in HIV-associated nonalcoholic fatty liver disease in a randomized, double-blind, multicenter trial ^[9], and visceral fat reduction has been linked to improved liver enzymes in HIV ^[10]. More recent work looked at safety and efficacy in people with HIV specifically on integrase inhibitor regimens, a population that wasn't well represented in the original trials ^[11]. A 2026 meta-analysis of randomized controlled trials pooled body composition, hepatic fat, and metabolic and safety outcomes for tesamorelin in HIV-associated lipodystrophy ^[12]. None of this trial evidence involves compounded or gray-market product, only the manufactured drug studied under IND and NDA processes. If a COA is the only quality documentation behind what you're buying, you're outside the population and product that generated this evidence base. For a fuller breakdown of onset and expected timelines from the trial data, see our article on how long does tesamorelin take to work.

How do I know if I'm buying compounded tesamorelin versus the approved drug?

Ask directly whether the product is Egrifta (brand-name, FDA-approved, NDC-numbered) or a compounded formulation from a 503A/503B pharmacy. Egrifta ships with FDA-regulated labeling and a specific National Drug Code; you can verify it against Drugs@FDA [Drugs@FDA]. Compounded tesamorelin should come from a licensed pharmacy that can name its bulk API supplier and, ideally, share the API-level COA on request, though as covered above that document doesn't fully vouch for the finished product. If a seller can't tell you which category their product falls into, or dodges the question, that's the actual red flag. That matters more than any single line item on a COA. A provider-reviewed sourcing pathway, where a prescriber and a named pharmacy partner are both identifiable, is the practical way most patients navigate this without becoming amateur analytical chemists. For the practical side of using an approved or compounded product correctly once sourced, see our guide on tesamorelin how to inject.

What are the known side effects and safety signals from the approved trials?

The phase 3 program and subsequent literature give a reasonably clear safety picture for the approved indication. Injection site reactions are common. Fluid retention, joint pain (arthralgia), and effects on glucose tolerance have been reported, consistent with other agents that raise IGF-1 through the growth hormone axis ^{[3] [4]}. A review of tesamorelin's use in HIV-associated lipodystrophy summarizes these tolerability findings across the trial program ^[13]. Tesamorelin also affects inflammatory markers. One analysis found a relationship between visceral fat reduction and changes in inflammatory markers in HIV patients with excess abdominal fat ^[14]. Population pharmacokinetic modeling in HIV-infected patients and healthy subjects has characterized dosing and clearance, informing the standard 2 mg daily subcutaneous regimen ^[15]. None of this safety data was generated on compounded product or unverified 'research' vials. If your source relies purely on a COA rather than pharmacy licensure and prescriber oversight, you're accepting that the safety data doesn't directly map onto what's in your vial.

Can a COA tell me anything about sterility or endotoxin risk?

Yes, if it includes the right tests, but most consumer-facing COAs don't. A real sterility test (USP <71> or equivalent) and a bacterial endotoxin test (USP <85>, typically reported in EU/mL) are standard for anything meant to be injected. Absence of these two tests on a COA for an injectable peptide is a serious gap, not a minor omission. Even when present, these tests apply to the batch tested, at the time it was tested. Reconstituted peptide, stored improperly or held past its stability window, can still develop contamination risk that no pre-shipment COA captured. This is a structural limitation of COAs generally, not specific to tesamorelin. It matters more for an injectable than for an oral supplement, though. There's no way around that. Once you have a legitimately sourced product in hand, proper injection technique still matters; see tesamorelin how to inject for the mechanics.

Does an FDA bulk drug substance listing mean tesamorelin is approved for compounding?

Being nominated for or included on FDA's list of bulk drug substances considered for use in compounding under section 503A is a regulatory status, not a safety or efficacy endorsement. FDA maintains the current nominated substances list ^[16] and the broader guidance on bulk drug substances used in compounding under 503A ^[17]. Compounders and buyers sometimes conflate 'FDA has this substance on a list' with 'FDA approved this for my use,' and those are different things entirely. A substance appearing on a bulks list, or a COA existing for a given lot, tells you about regulatory eligibility and batch testing. It tells you nothing about whether compounded tesamorelin for a given off-label use has trial-level evidence behind it, because it doesn't.

How does tesamorelin's evidence quality compare to other injectable peptides?

Tesamorelin holds a genuinely different evidentiary position than most peptides discussed in the broader injectable-peptide space. Recent reviews aimed at orthopaedic and sports medicine physicians have surveyed the injectable peptide landscape broadly, noting that most peptides marketed for musculoskeletal or performance use lack the randomized controlled trial base that tesamorelin has ^{[1] [18]}. A 2026 review specifically covering safety and efficacy of approved versus unapproved peptide therapies for musculoskeletal injuries and athletic performance draws the same distinction. Approved drugs like tesamorelin sit in a different evidence tier than compounded or research-labeled peptides marketed for similar goals ^[19]. That gap is exactly why the COA conversation exists for tesamorelin at all. Nobody asks for a certificate of analysis on an FDA-approved tablet from a retail pharmacy. People ask for one on tesamorelin specifically when the product in question has stepped outside that approved, inspected supply chain. Worth remembering, if you take one thing from this whole article.

Frequently asked questions

Do I need to see a certificate of analysis before using tesamorelin?

If you're receiving FDA-approved Egrifta through a licensed pharmacy, no, the manufacturing is already under FDA oversight. If you're being offered a compounded or 'research' tesamorelin product and a COA is the only quality proof offered, treat that as a signal you're outside the approved supply chain, not as full reassurance on its own.

What's the difference between a COA for raw tesamorelin powder and for the finished injectable?

A raw-material COA tests the bulk peptide powder before compounding: identity, purity, residual solvents. A finished-product test would need to cover the reconstituted, sterile, dosed product a patient actually injects. Most COAs shown to consumers are raw-material documents and don't address sterility or accuracy of the final compounded vial.

Can a certificate of analysis be faked or reused?

Yes. A COA is only as trustworthy as the lab issuing it and the chain of custody linking it to the specific vial in hand. Reused, altered, or seller-generated 'COAs' with no accredited third-party lab named are a known problem in the peptide gray market and can't be verified by a buyer without contacting the lab directly.

Is tesamorelin FDA-approved for general fat loss or anti-aging?

No. Egrifta is approved specifically for reducing excess visceral adipose tissue in HIV-infected patients with lipodystrophy ^[3][4]. Use for general weight loss, anti-aging, or bodybuilding purposes is off-label, meaning it falls outside the population and endpoints studied in the phase 3 trials that earned FDA approval.

What lab tests should appear on a legitimate tesamorelin COA?

Look for a matching lot number, a numeric HPLC purity result with stated method, a mass spectrometry identity confirmation, and, for anything injectable, sterility and bacterial endotoxin results with numeric limits. A COA missing sterility/endotoxin data for an injectable peptide is missing something that matters.

Does the FDA bulk drug substances list mean a compounded version is safe?

Being on FDA's nominated bulk drug substances list under 503A ^[16] is a regulatory eligibility status for compounding pharmacies, not a safety or efficacy endorsement. It says the substance can legally be considered for compounding under certain conditions; it says nothing about a specific compounder's process or a specific batch's quality.

How is compounded tesamorelin regulated differently from Egrifta?

Egrifta went through FDA's new drug approval pathway with phase 3 trials. Compounded tesamorelin is made under 21 U.S.C. 353a and the bulk substance rules at 21 CFR 216.23 (503A) or 216.24 (503B) ^[5][6][7], which govern sourcing and compounding practice but don't require the same premarket efficacy trials as an approved drug.

What side effects does the tesamorelin trial data show?

The phase 3 program and follow-up studies report injection site reactions, fluid retention, joint pain, and effects on glucose tolerance tied to the growth hormone/IGF-1 axis ^[3][13]. Inflammatory marker changes have also been studied alongside visceral fat reduction ^[14]. These findings come from trials on the manufactured drug, not compounded or gray-market product.

How long does tesamorelin take to show visceral fat reduction?

The phase 3 trials that support FDA approval measured visceral adipose tissue changes over defined treatment periods; for the specific timeline breakdown, see our companion article on how long tesamorelin takes to work, which draws on the same trial data referenced here ^[8].

Why do sellers of compounded tesamorelin emphasize their COA so heavily?

Because a COA is the main quality claim available to a product that sits outside FDA drug approval. It substitutes, imperfectly, for the manufacturing oversight, inspection, and trial evidence that come automatically with an approved drug. A heavy COA emphasis is often a marker that you're being sold something outside that approved pathway.

Can tesamorelin be detected in anti-doping testing, and does that relate to COAs?

Yes, GHRH analogues including tesamorelin are targets of specific detection methods developed for sports anti-doping testing ^[2]. This is a separate issue from consumer COAs, but it shows the molecule and its degradation products are well characterized analytically, which is part of why legitimate identity testing on a COA is achievable when a lab actually does it properly.

Should I trust a COA from the same company selling me the product?

Be skeptical. Independent, accredited third-party lab testing is the standard that makes a COA meaningful. A COA generated or commissioned entirely in-house by the seller, with no independent lab named or verifiable, carries much less weight and shouldn't be treated as equivalent to third-party verification.

Sources

1. PubMed, Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (PMID 41476424): Peptide manufacturing failure modes such as truncated or degraded sequences are a recognized quality concern in injectable peptide products.
2. PubMed, Advances in the detection of growth hormone releasing hormone synthetic analogs (PMID 34665524): Analytical detection methods for GHRH synthetic analogues, including tesamorelin, have been developed largely for anti-doping and quality testing purposes.
3. PubMed, Tesamorelin (PMID 21283099): Tesamorelin is characterized as a growth hormone-releasing factor analogue with an approved indication and defined safety profile.
4. PubMed, Tesamorelin (PMID 31644039): Tesamorelin's approved use is for reduction of visceral adipose tissue in HIV-associated lipodystrophy, with associated tolerability findings.
5. eCFR, 21 CFR 216.23 (503A Bulks List): Bulk drug substances used in 503A pharmacy compounding are governed by this specific federal regulation.
6. eCFR, 21 CFR 216.24 (503B Bulks List): Bulk drug substances used in 503B outsourcing facility compounding are governed by this specific federal regulation.
7. Cornell Law School (Legal Information Institute), 21 U.S.C. 353a: Pharmacy compounding of drug products, including from bulk substances, is governed by this federal statute.
8. PubMed, Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: pooled phase 3 analysis (PMID 20554713): Two multicenter, double-blind, placebo-controlled phase 3 trials with safety extension data support tesamorelin's approved effect on visceral adipose tissue.
9. PubMed, Effects of tesamorelin on non-alcoholic fatty liver disease in HIV (PMID 31611038): A randomized, double-blind, multicenter trial found tesamorelin reduced liver fat in HIV-associated NAFLD.
10. PubMed, Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV (PMID 28832410): Visceral fat reduction from tesamorelin correlated with improved liver enzyme levels in HIV patients.
11. PubMed, Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors (PMID 38905488): Tesamorelin's efficacy and safety have been specifically evaluated in HIV patients on integrase inhibitor regimens.
12. PubMed, Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin: meta-analysis of RCTs (PMID 41545261): A 2026 meta-analysis pooled randomized controlled trial data on tesamorelin's body composition, hepatic fat, and safety outcomes in HIV-associated lipodystrophy.
13. PubMed, Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy (PMID 21668043): Tolerability findings including injection site reactions, fluid retention, and arthralgia are summarized across the tesamorelin trial program.
14. PubMed, Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat (PMID 21516030): Tesamorelin's effect on inflammatory markers relates to the degree of visceral adipose tissue reduction in HIV patients.
15. PubMed, Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects (PMID 25358450): Population pharmacokinetic modeling characterized tesamorelin dosing and clearance in HIV-infected and healthy populations.
16. FDA, Bulk drug substances nominated for use in compounding under section 503A (current list): FDA maintains a current list of bulk drug substances nominated for use in compounding, distinct from full drug approval status.
17. FDA, Bulk drug substances used in compounding under section 503A of the FD&C Act: FDA guidance describes the regulatory framework for bulk drug substances used in 503A compounding.
18. PubMed, Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (PMID 41490200): A 2026 review surveys applications and evidence challenges for therapeutic peptides used in orthopaedic contexts.
19. PubMed, Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (PMID 41966639): A 2026 review distinguishes the evidence tier of FDA-approved peptide drugs from unapproved, compounded peptide products marketed for similar uses.